🚀 VC round data is live in beta, check it out!
Paxman Valuation Multiples
Discover revenue and EBITDA valuation multiples for Paxman and similar public comparables like Aroa Biosurgery, Edap TMS, Hyperfine, Onyx Healthcare and more.
Paxman Overview
About Paxman
Paxman AB is a Sweden based company engaged in the development of PAXMAN Scalp Cooling System that is used to minimize hair loss in connection with chemotherapy treatment. The company offers a stand-alone, mobile electric cooling unit, which is a liquid-based cooling system that cools down the patient's scalp through the silicone hat. Geographically the company markets its product to Great Britain, Scandinavian countries, the Netherlands, Belgium, and Australia.
Founded
2016
HQ
Employees
105
Website
Financials (LTM)
EV
$121M
Paxman Financials
Paxman reported last 12-month revenue of $39M and EBITDA of $5M.
In the same LTM period, Paxman generated $25M in gross profit, $5M in EBITDA, and had net loss of ($152K).
Revenue (LTM)
Paxman P&L
In the most recent fiscal year, Paxman reported revenue of $35M and EBITDA of $3M.
Paxman expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $39M | XXX | $35M | XXX | XXX | XXX |
| Gross Profit | $25M | XXX | $23M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | $5M | XXX | $3M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 9% | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 1% | XXX | XXX | XXX |
| Net Profit | ($152K) | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | (0%) | XXX | (5%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Paxman Stock Performance
Paxman has current market cap of $132M, and enterprise value of $121M.
Market Cap Evolution
Paxman's stock price is $5.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $121M | $132M | 0.3% | XXX | XXX | XXX | $-0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPaxman Valuation Multiples
Paxman trades at 3.1x EV/Revenue multiple, and 26.1x EV/EBITDA.
EV / Revenue (LTM)
Paxman Financial Valuation Multiples
As of April 20, 2026, Paxman has market cap of $132M and EV of $121M.
Equity research analysts estimate Paxman's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Paxman has a P/E ratio of (872.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $132M | XXX | $132M | XXX | XXX | XXX |
| EV (current) | $121M | XXX | $121M | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 26.1x | XXX | 38.5x | XXX | XXX | XXX |
| EV/EBIT | 75.4x | XXX | 259.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | 5.3x | XXX | XXX | XXX |
| P/E | (872.5x) | XXX | (72.5x) | XXX | XXX | XXX |
| EV/FCF | (204.9x) | XXX | (68.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Paxman Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Paxman Margins & Growth Rates
Paxman's revenue in the last 12 month grew by 38%.
Paxman's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Paxman's rule of 40 is 59% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Paxman's rule of X is 123% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Paxman Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 38% | XXX | 40% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 124% | XXX | 159% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 59% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 123% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Paxman Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Paxman | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Edap TMS | XXX | XXX | XXX | XXX | XXX | XXX |
| Hyperfine | XXX | XXX | XXX | XXX | XXX | XXX |
| Onyx Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| CROSSJECT | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Paxman M&A Activity
Paxman acquired XXX companies to date.
Last acquisition by Paxman was on XXXXXXXX, XXXXX. Paxman acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Paxman
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPaxman Investment Activity
Paxman invested in XXX companies to date.
Paxman made its latest investment on XXXXXXXX, XXXXX. Paxman invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Paxman
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Paxman
| When was Paxman founded? | Paxman was founded in 2016. |
| Where is Paxman headquartered? | Paxman is headquartered in Sweden. |
| How many employees does Paxman have? | As of today, Paxman has over 105 employees. |
| Is Paxman publicly listed? | Yes, Paxman is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Paxman? | Paxman trades under PAX ticker. |
| When did Paxman go public? | Paxman went public in 2017. |
| Who are competitors of Paxman? | Paxman main competitors are Aroa Biosurgery, Edap TMS, Hyperfine, Onyx Healthcare. |
| What is the current market cap of Paxman? | Paxman's current market cap is $132M. |
| What is the current revenue of Paxman? | Paxman's last 12 months revenue is $39M. |
| What is the current revenue growth of Paxman? | Paxman revenue growth (NTM/LTM) is 38%. |
| What is the current EV/Revenue multiple of Paxman? | Current revenue multiple of Paxman is 3.1x. |
| Is Paxman profitable? | Yes, Paxman is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Paxman? | Paxman's last 12 months EBITDA is $5M. |
| What is Paxman's EBITDA margin? | Paxman's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Paxman? | Current EBITDA multiple of Paxman is 26.1x. |
| What is the current FCF of Paxman? | Paxman's last 12 months FCF is ($589K). |
| What is Paxman's FCF margin? | Paxman's last 12 months FCF margin is (2%). |
| What is the current EV/FCF multiple of Paxman? | Current FCF multiple of Paxman is (204.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.